April 23, 2014 / 5:45 AM / 3 years ago

BRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie

April 23 (Reuters) - Ablynx NV

* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie

* Upon achievement of pre-defined phase II success criteria, Abbvie will exercise its right to in-license ALX-0061

* Study will assess pharmacodynamics, safety, tolerability and immunogenicity of single SC and IV doses of ALX-0061 in healthy subjects Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below